Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Moyamoya Disease Market size was valued at USD 1.39 billion in 2024 and is likely to cross USD 2.89 billion by 2037, registering more than 5.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of moyamoya disease is assessed at USD 1.46 billion.
The rising incidence of moyamoya disease in females, particularly in those under 20, is responsible for the market's expansion. With a female-to-male ratio of 1.8, the prevalence for men and women was 11.5 and 20.6 correspondingly across the globe.
In addition, it is mentioned that the main driver of the moyamoya disease market is rising public awareness. People are becoming more knowledgeable about the various kinds of neurological illnesses these days. Through conferences and seminars, the government and other organizations have been educating the public about diseases and hygiene. People are growing more attentive of their health and more aware. Consequently, rising awareness has propelled the market's expansion. Both fresh and seasoned marketers are helping to manage this situation. For example, the FDA approved Silk Road Medical, Inc.'s next-generation ENROUTE Trans carotid Neuroprotection System (NPS) on April 13, 2016. The NPS is intended and specifically built for the revascularization of the carotid arteries.
Moyamoya Disease Sector: Growth Drivers and Challenges
Growth Drivers
-
Rise in Research and Development- Growing R&D and better reimbursement practices in the healthcare industry will boost market growth. Other important factors driving the moyamoya disease drug market growth include improved healthcare outcomes, increased government support, and rising healthcare outcomes. R&D expenditures worldwide have risen to a record high of about USD 1.7 trillion. Approximately 10 nations make up 80% of the spending. Countries have committed to significantly increasing public and corporate R&D spending as well as the number of researchers by 2030 as part of the Sustainable Development Goals (SDGs).
-
Increasing Technological Developments- Throughout the projection period of 2024–2036, the market for medications treating moyamoya disease will witness considerable growth due to rising healthcare device modernization and technical breakthroughs, as well as increased demand from emerging economies. For every medical equipment they utilize, the average American pays roughly USD 400. Diagnostic imaging technologies including MRIs and angiographies have improved with time, leading to more accurate and timely diagnosis of moyamoya disease. Better patient outcomes and timely intervention are made possible by this. For every million individuals in the US, there are at least 40 magnetic resonance imaging (MRI) facilities available. With 149.2 MRIs performed per 1,000 persons in 2019, Germany was the country with the largest number of exams performed.
-
Collaborations and Partnerships- Cooperation amongst academic institutions, pharmaceutical corporations, and regulatory agencies can speed up the development of novel treatments and enhance patient care by facilitating the sharing of information and resources.
Challenges
-
Limited Treatment Options- There are currently few alternatives for treating moyamoya illness. The main strategies are surgical procedures like direct bypass or indirect revascularization. The market's expansion is hampered by the absence of efficient medical treatments.
-
Moyamoya disease surgery and long-term care can be costly, particularly in areas with inadequate healthcare resources. For some individuals, access is hampered by the high expenses of treatment.
-
Moyamoya illness is frequently misdiagnosed or underdiagnosed, especially in underdeveloped areas where access to specialized medical treatment is scarce. The early detection and prompt response are hampered by a lack of knowledge and diagnostic resources.
Moyamoya Disease Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.8% |
|
Base Year Market Size (2024) |
USD 1.39 billion |
|
Forecast Year Market Size (2037) |
USD 2.89 billion |
|
Regional Scope |
|
Moyamoya Disease Segmentation
Drug Type (Blood Thinners, Calcium Channel Blocker, Anti-Seizure Medications)
The calcium channel blocker segment in the moyamoya disease market is anticipated to hold a notable share of about 53% in the moyamoya disease drug market over the forecast period on account of the increasing usage of calcium channel blockers to control and lessen stroke symptoms. Every 40 seconds, a stroke occurs, and every 4 minutes, a stroke-related death occurs. Stroke causes more than 140,000 fatalities annually. According to statistics, women account for 60% of stroke deaths while men account for 40%. In addition, in one patient, the incidence of headaches, seizures, and transient ischemia events decreased, while there were no more incidents in the other patient.
End-User (Hospitals, Pharmacies)
The hospitals segment is attributed to hold the largest share of 72% because of the large number of patients, this raises the need for medications in hospitals. In the US, one in a million persons suffer from Moyamoya disease. Children are the disease's primary victims. While adults can also be diagnosed, children are often diagnosed at the age of 7.
Our in-depth analysis of the global market includes the following segments:
|
Drug Type |
|
|
Diagnosis |
|
|
Treatment |
|
|
End-User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Moyamoya Disease Industry - Regional Synopsis
North American Market Forecast
North America industry is poised to account for largest revenue share of 33% by 2037, impelled by development of novel and cutting-edge technology in the region. Major pharmaceutical businesses operating in the area and significant investments being made in the development of novel and cutting-edge pharmaceuticals are the main drivers of the market's growth in this region. Moreover, there has been an increase in the number of people facing problems due to obesity in the region. The United States also has one of the largest percentages of obese people worldwide. Data gathered between 2017 and 2020 indicates that 41.9% of adult Americans are obese. From 2017 to March 2020, the US had a 41.9% obesity prevalence rate.
APAC Market Statistics
The moyamoya disease market in the Asia Pacific region is projected to hold the second-largest share of about 27% during the projected period. The growth of the market in this region is owing to the increasing prevalence of moyamoya disease in the region, backed by the busy and hectic lifestyle of people. Furthermore, improving healthcare facilities is also estimated to boost market growth.
Companies Dominating the Moyamoya Disease Landscape
- Abbott Laboratories
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- Siemens Healthcare GmbH
- Boston Scientific Corporation
- Johnson & Johnson Services, Inc.
- Valenta Pharmaceuticals Company
- Novartis AG
- Sanofi-Aventis Groupe
- AbbVie Inc.
- Elli Lilly and Company
Recent Developments
- Merck's blood vessel disorder therapy receives US FDA's priority review. Merck said on Thursday the U.S. health regulator will review its experimental therapy to treat a type of progressive blood vessel disorder on a priority basis. The drugmaker had gained rights to the therapy, sotatercept, through its USD 11.5 billion acquisition of Acceleron Pharma in 2021. The U.S. Food and Drug Administration has set March 26, 2024 as a target action date for the review, Merck said. If approved, the therapy will help the U.S. drugmaker diversify its revenue stream as its blockbuster cancer immunotherapy, Keytruda, moves towards loss of market exclusivity in 2028.
- Valenta Pharm launches a new generation antioxidant. Ethoxidol – is a new original second generation1 antioxidant for treatment of chronic ischemia of brain (cerebrovascular failure) introduced Valenta Pharm. Existing antioxidants operating under conditions of ischemia acute at a time of process slow growth can’t unlock own effect. An additional mechanism of an organism adaptation in ischemia slow has inaugurated recently - in the 1990s about. This discovery has led to new medicines development. Ethoxidol – is a second-generation antioxidant for treatment of chronic ischemia of brain. The unique mechanism of Ethoxidol is the distribution of energy inside brain cells and stimulation own antioxidant system of organism. Therefore, we believe that of applications of Ethoxidol will enable the doctors to deal with ischemia acute chronic diseases and will prevent of acute vascular disasters.
- Report ID: 3383
- Published Date: Jan 03, 2025
- Report Format: PDF, PPT
Have specific data needs or budget constraints?
Reach out to us for a customized quote or to learn more about our special pricing
for startups and universities
Frequently Asked Questions (FAQ)
Moyamoya Disease Drug Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
